Sandeep Grewal, MD
Hematology & Oncology · Flint, MINPI 1932315124
Payments from drug & device makers
Across 116 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$256
- Takeda Pharmaceuticals U.S.A., Inc.$226
- Amgen$186
- AstraZeneca$150
- Bayer$138
- Exelixis Inc.$130
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,26188%
- Education$30912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $226 |
| Amgen | 10 | $186 |
| AstraZeneca(2 entities) | 9 | $150 |
| Bayer | 3 | $138 |
| Exelixis Inc. | 3 | $130 |
| Merck | 7 | $121 |
| Eisai Inc. | 2 | $116 |
| Gilead(2 entities) | 2 | $113 |
| Genentech USA, Inc. | 7 | $102 |
| Bristol Myers Squibb | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Novartis | 4 | $77 |
| Taiho Oncology, Inc. | 3 | $61 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $56 |
| Pfizer | 4 | $53 |
| Epizyme, Inc. | 2 | $48 |
| Sanofi | 3 | $47 |
| EMD Serono, Inc. | 1 | $44 |
| Agios Pharmaceuticals, Inc. | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Beigene USA, Inc. | 2 | $32 |
| Seagen Inc. | 2 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 2 | $27 |
| Dova Pharmaceuticals | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Mylan Institutional Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $17 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,570 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 66 | $914,924 |
| IbrancePalbociclib | 52 | $781,194 |
| PromactaEltrombopag Olamine | 49 | $669,706 |
| RevlimidLenalidomide | 42 | $663,354 |
| Lenalidomide | 51 | $638,019 |
| TasignaNilotinib Hcl | 32 | $630,253 |
| PomalystPomalidomide | 24 | $565,573 |
| CalquenceAcalabrutinib Maleate | 34 | $405,486 |
| BrukinsaZanubrutinib | 39 | $383,791 |
| VerzenioAbemaciclib | 22 | $317,780 |
| InlytaAxitinib | 20 | $309,808 |
| JakafiRuxolitinib Phosphate | 18 | $291,913 |
| EliquisApixaban | 266 | $229,485 |
| LynparzaOlaparib | 12 | $188,817 |
| LumakrasSotorasib | 12 | $186,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis, Bosulif, Retacrit | $53 | $1,461,004361 claims |
| NovartisPromacta, Tasigna | $77 | $1,299,95981 claims |
| Astellas Pharma US IncXtandi | $27 | $914,92466 claims |
| Bristol Myers SquibbRevlimid | $94 | $663,35442 claims |
| AstraZenecaCalquence, Lynparza | $150 | $594,30246 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $86 | $565,57324 claims |
| Beigene USA, Inc.Brukinsa | $32 | $383,79139 claims |
| Lilly USA, LLCVerzenio | $56 | $317,78022 claims |
| AmgenLumakras | $186 | $186,24412 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $179,88937 claims |
| Johnson & JohnsonXarelto | $256 | $52,54764 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $226 | $30,46212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Flint
- Madan AroraFlint$84K
- Paul AdamsFlint$76K
- Rizwan DanishFlint$49K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.